key: cord-0266234-xqsfl9oz
authors: Albornoz, Eduardo; Amarilla, Alberto A; Modhiran, Naphak; Parker, Sandra; Li, Xaria X.; Wijesundara, Danushka K.; Zamora, Adriana Pliego; McMillan, Christopher LD; Liang, Benjamin; Peng, Nias Y.G.; Sng, Julian D.J.; Saima, Fatema Tuj; Paramitha, Devina; Parry, Rhys; Avumegah, Michael S.; Isaacs, Ariel; Lo, Martin; Miranda-Chacon, Zaray; Bradshaw, Daniella; Salinas-Rebolledo, Constanza; Rajapakse, Niwanthi W.; Munro, Trent; Rojas-Fernandez, Alejandro; Young, Paul R.; Stacey, Katryn J; Khromykh, Alexander A.; Chappell, Keith J.; Watterson, Daniel; Woodruff, Trent M.
title: SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike-ACE2 receptor interaction
date: 2022-01-12
journal: bioRxiv
DOI: 10.1101/2022.01.11.475947
sha: c3c91c15732c79fc5e068f0602433251f66083a0
doc_id: 266234
cord_uid: xqsfl9oz

Coronavirus disease-2019 (COVID-19) is primarily a respiratory disease, however, an increasing number of reports indicate that SARS-CoV-2 infection can also cause severe neurological manifestations, including precipitating cases of probable Parkinson’s disease. As microglial NLRP3 inflammasome activation is a major driver of neurodegeneration, here we interrogated whether SARS-CoV-2 can promote microglial NLRP3 inflammasome activation utilising a model of human monocyte-derived microglia. We identified that SARS-CoV-2 isolates can bind and enter microglia, triggering inflammasome activation in the absence of viral replication. Mechanistically, microglial NLRP3 could be both primed and activated with SARS-CoV-2 spike glycoprotein in a NF-κB and ACE2-dependent manner. Notably, virus- and spike protein-mediated inflammasome activation in microglia was significantly enhanced in the presence of α-synuclein fibrils, which was entirely ablated by NLRP3-inhibition. These results support a possible mechanism of microglia activation by SARS-CoV-2, which could explain the increased vulnerability to developing neurological symptoms akin to Parkinson’s disease in certain COVID-19 infected individuals, and a potential therapeutic avenue for intervention. SIGNIFICANCE STATEMENT Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) principally affects the lungs, however there is evidence that the virus can also reach the brain and lead to chronic neurological symptoms. In this study, we examined the interaction SARS-CoV-2 with brain immune cells, by using an ex-vivo model of human monocyte-derived microglia. We identified robust activation of the innate immune sensor complex, NLRP3 inflammasome, in cells exposed to SARS-CoV-2. This was dependent on spike protein-ACE2 receptor interaction and was potentiated in the presence of α-synuclein. We therefore identify a possible mechanism for SARS-CoV-2 and increased vulnerability to developing neurological dysfunction. These findings support a potential therapeutic avenue for treatment of SARS-CoV-2 driven neurological manifestations, through use of NLRP3 inflammasome or ACE2 inhibitors.

Keywords: SARS-CoV-2, NLRP3, Microglia, a-synuclein , Spike  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  INTRODUCTION  70 Neuroinflammation is a hallmark of neurodegenerative diseases. A variety of stimuli within 71 the central nervous system (CNS), including pathogens, injury, toxic metabolites, and protein 72 aggregates among others, can lead to the activation of the innate immune response mainly 73 through microglial activation. When chronically activated, this defence mechanism creates a 74 proinflammatory environment that drives neurodegeneration (1, 2). Microglia are resident 75 populations of macrophages in the CNS that respond to pathogen-associated molecular patterns 76 (PAMPs) and host-or environment-derived danger-associated molecular patterns (DAMPs) to 77 drive innate immune responses and inflammation within the brain. Recent evidence has 78 highlighted the role of intracellular protein complexes, known as the inflammasomes, in CNS 79 innate immunity. Alzheimer's disease (AD), and TDP43 and SOD1 aggregates in amyotrophic lateral sclerosis 87 (ALS) (5-7). Microglial NLRP3 inflammasome can also be activated by a variety of pathogenic 88 viruses with neurotropism such as Zika virus (ZIKV) and Japanese Encephalitis virus (JEV) 89 (8, 9) . The NLRP3 inflammasome is comprised of the NLRP3 protein, the adaptor molecule 90 apoptosis-associated speck-like protein containing a CARD (ASC), and caspase-1. Activation 91 of NLRP3 is a two-step process; a priming step usually mediated through a Toll-like receptor 92 involves NF-kB-dependent induction of both NLRP3 and pro-IL-1b, whereas the triggering 93 step leads to oligomerisation of NLRP3, recruitment of ASC, and recruitment and activation 94 of caspase-1. Active caspase-1 then cleaves pro-IL-1b and pro-IL-18 into their active forms, 95 and initiates pyroptotic cell death (10). 96

The hypothesis that viral infections can accelerate neurodegeneration is gaining attention with 97 relevance to the current COVID-19 pandemic (11, 12) . It has become clear that severe acute 98 respiratory syndrome coronavirus 2 (SARS-CoV-2) can invade and affect multiple organs and 99 tissues including the brain (13, 14). Post-mortem analysis of brains obtained from deceased 100 replication by monitoring infectious virus particle release after infection with multiplicity of 132 infection (MOI) of 1 and 0.1 To achieve this, we used an early clinical isolate of SARS-CoV-133 2, referred to here as D614 (27) . Notably, we found no secreted virus in the supernatant of 134 infected MDMi and mouse primary microglia (mMi) cell culture supernatants, which 135 contrasted to that in Vero E6 and Caco2 cells ( Figure 1C ), supporting the notion that microglia 136 cells do not support SARS-CoV-2 replication in vitro. 137

As angiotensin-converting enzyme 2 (ACE2) is the most well-characterized receptor for 138 SARS-CoV-2 cell attachment (28), and is expressed in the CNS, predominantly by glia, 139 neurons and neurovascular endothelium (29), we proceeded to determine the level of ACE2 in 140

MDMi by qPCR and western blot. We observed that MDMi expressed ACE2 mRNA, although 141 the levels were lower compared to Vero E6 and Caco2 cells ( Figure 1D ). Western blot analysis 142 from lysed microglia showed that ACE2 protein levels varied greatly in individual donors and 143 displayed a differential pattern of expression compared to Vero E6 and Caco2 cells ( Figure  144 1E). The control cells (VeroE6 and Caco2) showed an expected full-length size of the 145 glycosylated ACE2 form of approximately 120 KDa, while microglia cells showed molecular 146 weights of ~135 and ~100 kDa. Notably, similar patterns have been also found in endothelial 147 cells and heart tissue from COVID-19 patients (30, 31). 148

Given that MDMi expressed ACE2 receptor, yet did not support virus replication, we sought 149 to determine whether SARS-CoV-2 binds to the microglial cell surface. To address this, MDMi 150 were exposed to D614 at MOI of 1, incubated for 2 hours at 4℃ and then subjected to several 151 washes to remove all unbound particles. We found significant levels of viral RNA from bound 152 virus particle on the cell surface ( Figure 1F ), suggesting that SARS-CoV-2 can indeed bind to 153

MDMi. We next investigated whether virus binding could promote viral entry by using a 154 pseudo-virus entry assay as previously reported for SARS-CoV-2 (32, 33). MDMi were 155 transduced with SARS-CoV-2 pseudo-virus for 72 hours and titer was determined by luciferase 156 activity. We observed higher levels of intracellular luciferase activity in microglia cells 157 infected with the pseudo-virus compared to the non-glycoprotein control (NE) and this level 158 was comparable to pseudo-virus transduced VeroE6 cells ( Figure 1G ), suggesting that SARS-159

CoV-2 has the ability to enter human microglia cells. means + SEM from at least three different donors. *P < 0.05, **P < 0.01, and ***P < 0.001 184 and **** P < 0.0001 by two-way ANOVA test with Sidak's correction. 185

Microglia are the resident immune cells found in the CNS that patrol the brain sensing for 187 pathogens or damage-associated stress signal (35). To investigate microglial inflammasome 188 activation in response to SARS-CoV-2, we exposed MDMi cells to SARS-CoV-2 and 189 measured key inflammasome activation signals. MDMi were incubated with MOI of 1 of D614 190 isolate directly, or in LPS-primed cells. At 24-hour post infection, western blot and 191 immunocytochemistry was performed to examine markers of inflammasome activation ( Figure  192 2A-C). 193

We identified SARS-CoV-2 alone induced inflammasome activation in MDMi as measured by 194 the release of cleaved IL-1b in the supernatant of cells exposed to D614. This correlated with 195 increased levels of cleaved caspase-1, validating activation of the inflammasome (Figure 2A densitometric analysis (fold change against vehicle group) for cleaved IL-1b, cleaved caspase-205 1 (p20), and ASC in the supernatants of LPS-primed or unprimed MDMi treated with SARS-206

CoV-2 (D614) isolate for 24 hours are presented in (A-B) respectively. Expression of GAPDH 207 was determined in cell lysates. Immunofluorescence staining of primed or unprimed MDMi 208 treated with SARS-CoV-2 (D614)-for Tubulin is stained in green and the formation of a 209 characteristic inflammasome ASC speck (red) is shown in (C). LPS-Nigericin (Nig; 10μM, 1 210 hour) was used as a positive control. Scale bar, 20 μm. Inset magnified view of ASC specks. 211 DAPI (blue), 4′,6-diamidino-2-phenylindole). Data points are means + SEM from at least 212 three different donors. *P < 0.05, **P < 0.01, and ***P < 0.001 and **** P < 0.0001 by one-213 way analysis of variance (ANOVA) with Tukey's post hoc test. 214 215 SARS-CoV-2 spike protein activates the NLRP3 inflammasome in human microglia 216

Given that MDMi cells express ACE2 and that live virus activated MDMi independent of viral 217 replication, we next determined whether spike protein itself could trigger inflammasome 218 activation directly in human microglia. We previously designed a prefusion-stabilized SARS-219

CoV-2 spike protein (S-clamp) that resembles a closed trimeric prefusion conformation (36). 220

To further identify the mechanism of inflammasome activation by SARS-CoV-2, we first 221 produced low endotoxin S-clamp and a control trimeric fusion protein (F-clamp) from Nipah 222 virus and validated these proteins using SDS-PAGE, size exclusion chromatography and 223 ELISA ( Figure 3A -C). As expected, the monomeric molecular weight of the S-clamp and F-224 clamp monomers were 180 and 60 KDa, respectively ( Figure 3A ). Additionally, we also 225 confirmed that the majority of the S-clamp and F-clamp were presented in their trimeric form 226 using size-exclusion chromatography and maintained reactivity assessed by binding of key 227 specific antibodies ( Figure 3B and C). Next, we proceeded to expose LPS-primed MDMi with 228 different concentrations of S-clamp or control F-clamp protein as shown in a schematic 229 representation in Figure 3D and identified that spike protein (S-clamp), but not the control F-230 clamp, induced significantly increased levels of IL-1β in supernatants after 24 hours exposure 231 ( Figure 3E ). This activation was entirely ablated in the presence of MCC950, a selective 232 inhibitor of NLRP3, confirming that the spike protein of SARS-CoV-2 is able to activate the 233 NLRP3 inflammasome in LPS-primed microglia ( Figure 3E As spike protein is the major surface glycoprotein of the SARS-CoV-2 viral particle and 257 contains a receptor-binding domain (RBD) that recognises ACE2 (37), we hypothesized that 258 inflammasome activation is mediated by ACE2-RBD interaction. To address this, we first 259 produced a low endotoxin version of a soluble human ACE2 protein (hACE2-FcM) and 260 validated it in a neutralization assay. We found that the soluble human ACE2 protein blocked 261 SARS-CoV-2 entry into Vero E6 cells ( Figure 4A ) with 50% inhibitory concentration (IC50) 262 of 39 μg/mL, compared to control protein (NCAM-FcM) produced similar manner as hACE2-263 FcM ( Figure 4A ). Based on this finding, we complexed the soluble ACE2 protein with the S-264 clamp at a molar ratio of 5:1, respectively, incubated at 37℃ for 1 hour, and then used this 265 complex to treat MDMi. We found a complete inhibition of IL-1β secretion in culture 266 supernatants compared to S-clamp treatment alone ( Figure 4B ). Additionally, pre-treatment of 267

MDMi with the ACE2 inhibitor, MLN-4760, also significantly reduced spike protein induced 268 IL-1β release from LPS-primed MDMi ( Figure 4C ). Furthermore, to confirm that MDMi 269 activation is ACE2 dependent, we used a well characterised monoclonal antibody (3E8), Validation of low endotoxin anti-ACE2 (3E8) and anti-Hemagglutinin from influenza A H3 287 (CO5) proteins by SDS-PAGE and ELISA (D-E). Effect of 3E8 in blocking cells activation by 288 spike protein in pre-treatment of LPS-primed MDMi exposed to S-clamp (F). Data are means 289 + SEM from at least three different donors. *P < 0.05, **P < 0.01, and ***P < 0.001 and **** 290 P < 0.0001 by one-way analysis of variance (ANOVA) with Tukey's post hoc test. 291 292 293

We next evaluated if spike protein can also prime MDMi. To achieve this, MDMi were first 295 stimulated with S-clamp for 6 hours, then media containing S-clamp was removed and replaced 296 with fresh media and incubated with either ATP or nigericin for 1 hour as the inflammasome-297 activating signal, as shown in a schematic representation in Figure 5A . We observed a 298 significant IL-1β release for both activators in S-clamp-primed cells, in comparison with either 299 vehicle, S-clamp, ATP or nigericin alone, and the level was of a similar, but slightly reduced 300 magnitude to LPS-primed cells ( Figure 5B -C). We also confirmed an S-clamp priming effect 301 through immunocytochemistry, showing ASC speck formation in S-clamp-primed cells 302 activated with nigericin ( Figure 5D ), displaying a similar morphology to cells previously 303 primed with LPS and activated with nigericin used as a positive control ( Figure 2C ). 304

To test if NF-kB signalling pathway is required for inflammasome priming by spike protein, 305 we pre-treated MDMi with the NF-kB inhibitor, Bay 11-7082, before stimulation with S-clamp 306 and the addition of ATP or nigericin. We found a complete inhibition of IL-1β release ( Figure  307 5E), confirming S-clamp priming activity is mediated through the NF-kB pathway. Moreover, 308 after priming with S-clamp, and before activating with either ATP or nigericin, we treated the 309 cells with the NLRP3 inhibitor MCC950 and demonstrated a complete inhibition of IL-1β 310 secretion ( Figure 5E ), confirming as expected that nigericin and ATP triggered NLRP3 after 311 priming by spike protein. 312

Recently, it has been shown that SARS-CoV-2 triggers pyroptosis in human monocytes (39). 313 Therefore, we assayed whether S-clamp priming and nigericin inflammasome activation 314 triggered pyroptosis in MDMi. Pyroptosis was quantified using lactate dehydrogenase (LDH) 315 release, and the caspase-1 inhibitor VX-765 was used to selectively assess the role for 316 inflammasome activation in cell death. We observed that nigericin treatment of S-clamp 317 primed MDMi readily triggered caspase-1-dependent pyroptosis within 1 hour ( Figure 5F ) 318 which was significantly reduced in the presence of caspase-1 inhibitor VX-765. SARS-CoV-2 319 spike protein mediating priming of the inflammasome has recently be documented in 320 macrophages derived from COVID-19 patients (40). Our data now provides strong evidence 321 that SARS-CoV-2 spike protein can also prime the NLRP3 inflammasome through the NF-kB 322 pathway in human microglia. To examine the role of SARS-CoV2 spike protein in the context of a-synuclein microglial 358 inflammasome activation, we repeated the experimental paradigm with spike in presence of a-359 synuclein for 24 hours as shown in a schematic representation in Figure 6E . Performing 360 western blot for cleaved IL-1β, cleaved caspase-1 and ASC on supernatants, we confirmed 361 inflammasome activation with both spike and a-synuclein in MDMi, and a trend towards an 362 increase in cleaved IL-1β when a-synuclein and spike were combined ( Figure 6F -G). We next 363 proceeded to evaluate whether spike protein could prime MDMi for enhanced inflammasome 364 activation driven by a-synuclein. We therefore primed MDMi with S-clamp for 6 hours 365 followed by a-synuclein activation for 24 hours ( Figure 6H ). We confirmed by ELISA that no 366 significant IL-1β release was induced by either S-clamp priming or a-synuclein when 367 administered alone, however robust IL-1β release was found in S-clamp primed cells in the 368 presence of a-synuclein, at levels even greater than LPS-primed cells ( Figure 6H ). This result 369 correlated with ASC speck formation in S-clamp primed cells activated with a-synuclein 370 ( Figure 6I ). To confirm the S-clamp priming effect in this context was also mediated through 371 NF-kB signalling, we pre-treated cells with the NF-kB inhibitor Bay 11-7082 and demonstrated 372 a complete inhibition of cleaved IL-1β release ( Figure 6J ). Altogether, our data demonstrates 373 that SARS-CoV-2, and spike protein, can both prime and activate the NLRP3 inflammasome 374 in human microglia, also potentiating activation in the presence of a-synuclein, supporting a 375 possible risk factor for COVID-19 in Parkinson's disease and neurodegeneration. 376 377 virus entry (33). Additionally, this study also found low or undetectable levels of viral RNA in 428 hPSC-derived microglia exposed to infectious SARS-CoV-2, offering further evidence that 429 while ACE2 mediated viral uptake is possible, hPSC-derived microglia do not support SARS-430

CoV-2 replication (33). 431

We also show that SARS-CoV-2 can activate the inflammasome in human microglia, through 432 the read-out of cleaved IL-1b, cleaved caspase-1, and ASC speck formation in the supernatant 433 At the end of each treatment, supernatants were collected and LDH release was quantified 566 using an LDH assay kit (TOX7-Sigma) as per the manufacturer's instructions. Caspase-1 567 dependent LDH release that was inhibited by the caspase-1 inhibitor VX-765 (20 μM), was 568 used as a readout for pyroptosis as previously described (76). 

Pseudo-virus particles for SARS-CoV-2 were generated by using a lentiviral-based pseudo-634 particles system as previously described (32). Briefly, HEK293T cells were co-transfected with 635 the following plasmids: 1 μg of p8.91 (encoding a second-generation lentiviral packaging 636 plasmid for HIV-1 gag-pol), 1.5 μg of pCSFLW (firefly luciferase reporter gene) and, 1 μg of 637 plasmid encoding SARS-CoV2 spike (D614) with C-terminal 18 amino acid deletion using 638

Lipofectamine LTX Plus reagent (Invitrogen, USA) as per manufacturer's protocol. A non-639 glycoprotein control (NE) was also generated using the same combination of plasmids as For ELISA analysis, Nipah F-clamp, or SARS-CoV-2 S-clamp proteins were diluted to 2 672 µg/mL in PBS and coated overnight on Nunc MaxiSorp ELISA plates. The next day, plates 673 were blocked with 150 µL/well of 5% KPL Milk Diluent/Blocking Solution Concentrate 674 (SeraCare) in PBS with 0.05% Tween 20 (PBS.T) for 1 hour at room temperature. Blocking 675 buffer was removed, and serial dilutions of Nipah F-or SARS-CoV-2 S ectodomain-specific 676 antibodies, 5B3 and CR3022 (81), were added. Plates were incubated for 1 hour at 37 ˚C before 677 they were washed three times with water and patted dry. Next, an HRP-conjugated goat anti-678 human secondary antibody (ThermoFisher) was added, and the plates incubated for 1 hour at 679 37 ˚C. The plates were washed and dried as above before the addition of TMB Single Solution 680 chromogen/substrate (Invitrogen). Plates were allowed to develop for 5 minutes at room 681 temperature before the reaction was stopped by the addition of 2N H2SO4. Absorbance at 450 682 nm was read on a Varioskan LUX Multimode Microplate Reader (ThermoFisher). Data were 683 analysed using GraphPad Prism version 8 using a one site -specific binding model. 684

Nipah F-clamp and SARS-CoV-2 S-clamp proteins were further analysed for their oligomeric 686 state via size-exclusion chromatography using a Superdex 200 Increase 10/300 GL or Superose 687 6 Increase 10/300 GL column, respectively. Approximately 30-50 µg of protein in PBS was 688 loaded onto the column using an ÄKTA pure FPLC system at a flowrate of 0.5 mL/ minute. 689

The limulus amebocyte lysate (LAL) based testing of endotoxin levels of the purified proteins 690 were performed using Endosafe®-PTS TM device and cartridges according to the 691 manufacturer's protocol (Charles River). Additionally, low endotoxin levels for the soluble 692 hACE2, and monoclonal antibodies (3E8 and CO5) were also produced and validated by SDS-693 PAGE and ELISA. For ELISAs, 2µg/mL in PBS of S-clamp or recombinant hACE2 or 694 Hemagglutinin (HA) from influenza A H3 (Switzerland 2013) were coated overnight on Nunc 695

MaxiSorp ELISA plates and then used to validate the hACE2, 3E8 and CO5 proteins 696 respectively. The endotoxin levels were 1.1 EU/mg, 5.9 EU/mg, < 5 EU/mg, < 5 EU/mg and 697 124 EU/mg for SARS-CoV-2 S-clamp, Nipah F-clamp, hACE2, 3E8 and CO5 proteins, 698 respectively. 699

Recombinant human α-synuclein monomer was obtained from Proteos, and in vitro fibril 701 generation was performed with a final concentration of 2 mg/ml in phosphate-buffered saline 702 (PBS) by incubation at 37⁰C with agitation in an orbital mixer (400 rpm) for 7 days with daily 703 cycles of sonication used to break down fibrillar aggregates as outlined previously (5). The 704 generation of fibrillar α-synuclein species was confirmed by transmission electron microscopy 705 and Thioflavin T fluorescence prior to use. 706

Primary microglial cells were collected and lysed using RIPA buffer (ThermoFisher). Proteins 708 were separated in precast BioRad gradient (4-20%) gels. Proteins were then transferred to a 709 nitrocellulose membrane and blocked for 1 h at room temperature (RT) using fluorescence 710 western blocking buffer (Licor Bioscience). Membranes were washed 5 times with 5 min 711 incubations per wash using either PBS containing 0.05% Tween-20 or 712 tris(hydroxymethyl)aminomethane (Tris)-buffered saline containing 0.05% Tween-20. 713

Primary human/rabbit/mouse antibodies, diluted in either Licor blocking buffer or 5% bovine 714 serum albumin (BSA) solution, were then added to the membranes and incubated overnight at 715 4°C. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading controls. 716

Following 5 washes, respective infrared-dye or horseradish peroxidase (HRP) conjugated 717 secondary antibodies against primary antibodies was added to the membranes for 1 hour at RT. 718

Bands were visualised using either the Odyssey CLx imaging system (LI-COR) or enhanced 719 chemiluminescence via SuperSignal ® West Pico Plus Chemiluminescent Substrate (Thermo-720 Scientific) accordingly to manufacturer's instructions. Densitometric analysis was performed 721 using Image Studio Lite software and the normalized band intensities were expressed as fold 722 change over the control group. 723 724 ELISA 725

Human IL-1 beta/IL-1F2 Duoset ELISA kit (R&D Systems, Catalog # DY201 was used to 726 measure IL-1β in the supernatants of activated microglia. The assay was carried out according 727 to the manufacturer's instructions. 728

MDMI cells were fixed with 4% paraformaldehyde in PBS for 10min. Cells were 730 permeabilised with 0.1% triton X-100, subsequently washed three times in PBS, then blocked 731 with 3% donkey serum in PBS for 1 hr at room temperature. Following this, cells were 732 incubated for 2 hrs at room temperature with combinations of the following antibodies: rabbit 733 anti-TMEM (1:100), rabbit anti-ASC (1:250), and mouse anti-Tubulin (1:250). Cells were then 734 washed three times with PBS before incubating with secondary antibodies for 1 hr at room 735 temperature. Secondary antibodies used were Donkey anti-rabbit 555 (1:2000) and donkey 736

Inflammasomes in CNS Diseases

Inflammasomes in 775 neuroinflammatory and neurodegenerative diseases

The inflammasome: a molecular platform triggering 777 activation of inflammatory caspases and processing of proIL-beta

Inflammasomes in the CNS

Inflammasome inhibition prevents alpha-synuclein pathology and 782 dopaminergic neurodegeneration in mice

NLRP3 is activated in Alzheimer's disease and contributes to 784 pathology in APP/PS1 mice

The microglial NLRP3 inflammasome is activated by amyotrophic 786 lateral sclerosis proteins

NLRP3 inflammasome: key 788 mediator of neuroinflammation in murine Japanese encephalitis

Zika virus infection induces host inflammatory responses by 791 facilitating NLRP3 inflammasome assembly and interleukin-1beta secretion

The NLRP3 inflammasome: molecular activation 794 and regulation to therapeutics

Infectious agents and neurodegeneration

COVID-19 and neurological disorders: are 798 neurodegenerative or neuroimmunological diseases more vulnerable?

SARS-CoV-2 cell tropism and multiorgan infection

Multiorgan and Renal Tropism of SARS-CoV-2

COVID-19 neuropathology at Columbia University Irving Medical 805

Neuropathology of patients with COVID-19 in Germany: a post-807 mortem case series

Neurological associations of COVID-19

SARS-CoV-2 and the risk of Parkinson's disease: 811 facts and fantasy

Central nervous system complications associated with SARS-CoV-2 813 infection: integrative concepts of pathophysiology and case reports

Impaired olfaction and other prodromal features in the Parkinson 816 At-Risk Syndrome Study

A case of probable Parkinson's disease after SARS-CoV-2 infection

Acute hypokinetic-rigid syndrome following SARS-CoV-820 2 infection

Coronavirus Disease 2019 and Parkinsonism: A Non

COVID-19 and selective vulnerability to 824

Parkinson's disease

Is COVID-19 a Perfect Storm for Parkinson's 826 Disease?

A human microglia-like cellular model for assessing the effects of 828 neurodegenerative disease gene variants

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G 830 Increases Infectivity of the COVID-19 Virus

Molecular interaction and inhibition of SARS-CoV-2 binding to the 832 ACE2 receptor

The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 834 in the Human and Mouse Brains

Endothelial cells are not productively infected by SARS-CoV-2

Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 838 entry in cardiomyocyte

The SARS-CoV-2 Spike protein has a broad tropism for 840 mammalian ACE2 proteins

A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 842

Tropism and Model Virus Infection in Human Cells and Organoids

A versatile reverse genetics platform for SARS-CoV-2 and other 845 positive-strand RNA viruses

Immune surveillance in the central nervous system

Preclinical development of a molecular clamp-stabilised subunit 849 vaccine for severe acute respiratory syndrome coronavirus 2

Spike Glycoprotein-Mediated Entry of SARS Coronaviruses

ACE2-targeting monoclonal antibody as potent and broad-spectrum 854 coronavirus blocker

SARS-CoV-2 engages inflammasome and pyroptosis in human 856 primary monocytes

Long-lived macrophage reprogramming drives spike protein-858 mediated inflammasome activation in COVID-19

The 860 Inflammasome in Times of COVID-19

Inflammasome activation and pyroptosis in lymphopenic liver 862 patients with COVID-19

Inflammasomes are activated in response to SARS-CoV-2 864 infection and are associated with COVID-19 severity in patients

SARS-CoV-2 infects blood monocytes to activate NLRP3 and 866 AIM2 inflammasomes, pyroptosis and cytokine release

The microglial NLRP3 inflammasome is involved in human SARS-869

CoV-2 cerebral pathogenicity: A report of three post-mortem cases

Mechanisms of SARS-CoV-2 entry into 872 cells

Cell entry mechanisms of SARS-CoV-2

Macrophages and Dendritic Cells Are Not the Major Source of Pro-876

Inflammatory Cytokines Upon SARS-CoV-2 Infection

SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small 879 CD45(-) Precursors of Hematopoietic and Endothelial Cells and in Response to Virus 880

Spike Protein Activates the Nlrp3 Inflammasome

Severe Acute Respiratory 883

Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome

Severe acute respiratory syndrome coronavirus E protein 886 transports calcium ions and activates the NLRP3 inflammasome

Severe acute respiratory syndrome coronavirus ORF3a protein activates 889 the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC

SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to 892 induce hyperinflammation

Cutting edge: NF-kappaB activating pattern recognition and 894 cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 895 expression

SARS coronavirus spike protein-induced 897 innate immune response occurs via activation of the NF-kappaB pathway in human 898 monocyte macrophages in vitro

SARS-CoV-2 spike protein induces inflammation via TLR2-dependent 900 activation of the NF-kappaB pathway

Reverse engineering Lewy bodies: how far 902 have we come and how far can we go?

Neurological Complications of 904

COVID-19)

Neurological Complications 906 of Coronavirus Disease (COVID-19): Encephalopathy, MRI Brain and Cerebrospinal 907 Fluid Findings: Case 2

Alpha-Synuclein Expression Restricts RNA Viral Infections in 912 the Brain

Can infections trigger 914 alpha-synucleinopathies?

Serum and CSF alpha-synuclein levels do not change in 916 COVID-19 patients with neurological symptoms

Interactions of SARS-CoV-2 919 with the Blood-Brain Barrier

Nervous system involvement after infection with COVID-19 and other 921 coronaviruses

COVID-19-related neuropathology and microglial activation in 923 elderly with and without dementia

Neuroinvasion of SARS-CoV-2 in human and mouse brain

Neuroinvasion and Encephalitis Following Intranasal Inoculation of 927 SARS-CoV-2 in K18-hACE2 Mice

A mouse-adapted model of SARS-CoV-2 to test COVID-19 929 countermeasures

SARS-CoV-2 causes brain inflammation and 931 induces Lewy body formation in macaques

Deep spatial profiling of human COVID-19 brains reveals 934 neuroinflammation with distinct microanatomical microglia-T-cell interactions

The Effect of the COVID-19 Pandemic on People with Parkinson's 937 Disease

Effects of COVID-19 on Parkinson's Disease Clinical Features: A 939 Community-Based Case-Control Study

NLRP3 inhibitors stoke anti-inflammatory ambitions

C5aR2 Activation Broadly Modulates the 943

Signaling and Function of Primary Human Macrophages

The Ketone Body beta-946

An amplicon-based sequencing framework for accurately 949 measuring intrahost virus diversity using PrimalSeq and iVar

An Optimized High-Throughput Immuno-Plaque Assay for 952 SARS-CoV-2

National Center for Immunization and Respiratory Diseases 954 (NCIRD) (2021) CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel. p Acceptable 955 Alternative Primer and Probe Sets

Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial 957 Virus Vaccine Candidates

Human monoclonal antibody combination against SARS 959 coronavirus: synergy and coverage of escape mutants

anti-mouse 488 (1:2000). Following three washes in PBS, cells were incubated with DAPI 737(1:4000 in PBS) before being mounted with Prolong gold antifade medium (Invitrogen) for 738 fluorescent microscopy. 739

Images were collected using a Diskovery spinning disk confocal microscope (Andor/Nikon), 741 60XC CFI Plan Apochromat WI (NA 1.2) lens, with a disk pinhole size of 70um, and an Andor 742 Zyla 4.2 sCMOS camera (Andor, UK). Images were collected at 12-bit and 2048 x 2048 pixel 743 resolution. System settings, camera exposure times, and image brightness and contrast were 744 consistent across all samples and optimised on Imaris 9.1.0 (Bitplane, UK) to create 745 representative images for presentation. Samples were stained using the following fluorescent 746 secondary antibodies: Donkey anti-rabbit Alexa Fluor® 555, Donkey anti-mouse Alexa 747Fluor® 488, and DAPI nuclear stain (brand). These fluorophores were then captured using 748 laser lines 561nm, 488nm, and 405nm for excitation with appropriate filters to maximise 749 emission photon capture. Images were captured in a Z-stack for intracellular ASC speck 750 visualisation, with a step size of 0.15um. 751

All data were analysed using Prism software (GraphPad 9.1.2). For growth kinetics, a multiple 753 comparison using two-way ANOVA test with Sidak's correction was used to compare within 754 groups. Statistical significance was set at 95 % (p = 0.05). For PRNT, a nonlinear regression 755 with Inhibitor vs. response (three parameters) model was used to determine the best-fit curve. 756Data are represented as mean +/-s.e.m. from at least 3 experiments or donors. ANOVA 757 followed by Tukey's post-test was performed to compare all treatment groups in densitometries 758 and ELISA. *P < 0.05, **P < 0.01, and ***P < 0.001 denote statistically significant differences 759 between indicated groups.